Currently, there are three ongoing studies using niraparib, which are as follows: the first is assessing its efficacy in a cohort of metastatic melanomas with generic HR mutations (NCT03925350), the second is investigating its effect in different solid tumors, including uveal melanoma, carrying BAP1 and other DNA damage repair (DDR) mutations (NCT03207347) and the last one is studying different solid tumors, including melanoma with pathogenic or likely pathogenic PALB2 mutations (NCT05169437). This evidence concerns the gene BAP1 and uveal melanoma.